Forlong Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $14.8M

  • Investors
  • 15

Forlong General Information

Description

Developer of cytokine therapeutics designed to treat cancer and other serious diseases through synthetic immunology. The company offers engineered cytokine drug platforms, immune cell activation technologies, and biomolecular discovery capabilities, enabling pharmaceutical and healthcare organizations to advance targeted immunotherapies with improved therapeutic potential.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 1, Suzhou Science and Technology Innovation Park
  • Number 19 Yong'an Road, Hushu Pass Town
  • Suzhou, Jiangsu 215000
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Building 1, Suzhou Science and Technology Innovation Park
  • Number 19 Yong'an Road, Hushu Pass Town
  • Suzhou, Jiangsu 215000
  • China
+86 0512

Forlong Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Forlong Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 01-Sep-2026 $14.8M Completed Generating Revenue
5. Later Stage VC 04-May-2026 Completed Generating Revenue
4. Early Stage VC (Series A1) 29-Aug-2023 Completed Generating Revenue
3. Early Stage VC (Series A) 05-Feb-2023 Completed Generating Revenue
2. Early Stage VC 01-Nov-2021 $4.67M $4.67M Completed Generating Revenue
1. Seed Round 10-Nov-2019 Completed Startup
To view Forlong’s complete valuation and funding history, request access »

Forlong Patents

Forlong Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026105063-A1 Long-acting il-15 agonist for treating bladder cancer Pending 14-Nov-2024
WO-2025233861-A1 Long-acting il-15 agonist for treating tumor Pending 08-May-2024
US-20240076353-A1 Agonistic interleiukin 15 complexes and uses thereof Inactive 31-Aug-2022
US-20250136665-A1 Agonistic interleiukin 15 complexes and uses thereof Pending 31-Aug-2022
EP-4581060-A1 Agonistic interleukin 15 complexes and uses thereof Pending 31-Aug-2022 C07K14/7155
To view Forlong’s complete patent history, request access »

Forlong Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Forlong Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Changshu Kaisheng Southeast Venture Capital Management Growth/Expansion Minority
Detong Capital Venture Capital Minority
Fosun Health Capital Corporate Venture Capital Minority
GF Xinde Investment Management PE/Buyout Minority
Shanghai Qingyun Private Equity Fund Management Growth/Expansion Minority
You’re viewing 5 of 15 investors. Get the full list »

Forlong FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process